Profit

Glenmark inks $350 mn deal with Eli Lily

PUBLISHED ON: October 31, 2007 | Duration: 2 min, 22 sec

  
loading..
In a $350 million deal with US based Eli Lily, Glenmark Pharmaceuticals has out-licensed GRC 6211 and a few other smaller molecules with potential to treat pain. Glenmark has received an upfront payment of $45 million from Eli Lily and going forward the companies will share the benefits from the sales when it hits the market in 2012.
ALSO WATCH
आयुष्मान खुराना ने 'चंडीगढ़ करे आशिकी' का किया प्रमोशन

................................ Advertisement ................................

................................ Advertisement ................................

Listen to the latest songs, only on JioSaavn.com